Literature DB >> 32700645

Is interleukin-2 an optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis.

Xia Qiu1, Huiqing Wang1, Ying Tang2, Xiaojuan Su1, Long Ge3, Yi Qu1, Dezhi Mu1.   

Abstract

BACKGROUND: Latent tuberculosis infection (LTBI) is a huge reservoir for the deadlier TB disease. Accurate identification of LTBI is a key strategy to eliminate TB. Therefore, a systematic review and meta-analysis approach was used to assess diagnostic potential of IL-2 for LTBI.
METHODS: PubMed, Web of Science, the Cochrane Library and Embase were searched. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), area under the summary receiver operating characteristic curve (AUROC) and hierarchical summary receiver operating characteristic curve (HSROC) were estimated by bivariate and HSROC models.
RESULTS: Twenty-seven studies including 1404 participants and 1986 samples met the inclusion criteria. The pooled sensitivity, specificity, PLR, NLR, DOR and AUROC of IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls. For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR, DOR and AUROC of IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.
CONCLUSIONS: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals.

Entities:  

Keywords:  Interleukin-2; active tuberculosis; differentiation; latent tuberculosis infection; non-TB controls

Year:  2020        PMID: 32700645      PMCID: PMC7877967          DOI: 10.1080/07853890.2020.1800073

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  48 in total

1.  First evaluation of QuantiFERON-TB Gold Plus performance in contact screening.

Authors:  Lucia Barcellini; Emanuele Borroni; James Brown; Enrico Brunetti; Daniela Campisi; Paola F Castellotti; Luigi R Codecasa; Federica Cugnata; Clelia Di Serio; Maurizio Ferrarese; Delia Goletti; Marc Lipman; Paola M V Rancoita; Giulia Russo; Marina Tadolini; Elisa Vanino; Daniela M Cirillo
Journal:  Eur Respir J       Date:  2016-07-07       Impact factor: 16.671

2.  Improving T-cell assays for diagnosis of latent TB infection: Confirmation of the potential role of testing Interleukin-2 release in Iranian patients.

Authors:  S Mamishi; B Pourakbari; H Shams; M Marjani; S Mahmoudi
Journal:  Allergol Immunopathol (Madr)       Date:  2016-01-16       Impact factor: 1.667

Review 3.  Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis.

Authors:  Novel N Chegou; Jan Heyckendorf; Gerhard Walzl; Christoph Lange; Morten Ruhwald
Journal:  Eur Respir J       Date:  2013-12-05       Impact factor: 16.671

Review 4.  Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Leila C Kahwati; Cynthia Feltner; Michael Halpern; Carol L Woodell; Erin Boland; Halle R Amick; Rachel Palmieri Weber; Daniel E Jonas
Journal:  JAMA       Date:  2016-09-06       Impact factor: 56.272

5.  Multiple cytokines for the detection of Mycobacterium tuberculosis infection in children with tuberculosis.

Authors:  N Nausch; C Lundtoft; G Schulz; H Henckel; E Mayatepek; B Fleischer; F M Marx; M Jacobsen
Journal:  Int J Tuberc Lung Dis       Date:  2017-03-01       Impact factor: 2.373

6.  Diagnostic performance of GM-CSF and IL-2 in response to long-term specific-antigen cell stimulation in patients with active and latent tuberculosis infection.

Authors:  María Elvira Balcells; Cinthya Ruiz-Tagle; Camila Tiznado; Patricia García; Rodrigo Naves
Journal:  Tuberculosis (Edinb)       Date:  2018-08-13       Impact factor: 3.131

7.  Evaluation of the diagnostic potential of IP-10 and IL-2 as biomarkers for the diagnosis of active and latent tuberculosis in a BCG-vaccinated population.

Authors:  Sen Wang; Ni Diao; Chanyi Lu; Jing Wu; Yan Gao; Jiazhen Chen; Zumo Zhou; Heqing Huang; Lingyun Shao; Jialin Jin; Xinhua Weng; Ying Zhang; Wenhong Zhang
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

8.  Potential Role for Mycobacterium tuberculosis Specific IL-2 and IFN-γ Responses in Discriminating between Latent Infection and Active Disease after Long-Term Stimulation.

Authors:  Qin Sun; Wei Wei; Wei Sha
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

Review 9.  A Case for Antibodies as Mechanistic Correlates of Immunity in Tuberculosis.

Authors:  Jeffrey Y Kawahara; Edward B Irvine; Galit Alter
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

Review 10.  Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Authors:  Haileyesus Getahun; Alberto Matteelli; Ibrahim Abubakar; Mohamed Abdel Aziz; Annabel Baddeley; Draurio Barreira; Saskia Den Boon; Susana Marta Borroto Gutierrez; Judith Bruchfeld; Erlina Burhan; Solange Cavalcante; Rolando Cedillos; Richard Chaisson; Cynthia Bin-Eng Chee; Lucy Chesire; Elizabeth Corbett; Masoud Dara; Justin Denholm; Gerard de Vries; Dennis Falzon; Nathan Ford; Margaret Gale-Rowe; Chris Gilpin; Enrico Girardi; Un-Yeong Go; Darshini Govindasamy; Alison D Grant; Malgorzata Grzemska; Ross Harris; C Robert Horsburgh; Asker Ismayilov; Ernesto Jaramillo; Sandra Kik; Katharina Kranzer; Christian Lienhardt; Philip LoBue; Knut Lönnroth; Guy Marks; Dick Menzies; Giovanni Battista Migliori; Davide Mosca; Ya Diul Mukadi; Alwyn Mwinga; Lisa Nelson; Nobuyuki Nishikiori; Anouk Oordt-Speets; Molebogeng Xheedha Rangaka; Andreas Reis; Lisa Rotz; Andreas Sandgren; Monica Sañé Schepisi; Holger J Schünemann; Surender Kumar Sharma; Giovanni Sotgiu; Helen R Stagg; Timothy R Sterling; Tamara Tayeb; Mukund Uplekar; Marieke J van der Werf; Wim Vandevelde; Femke van Kessel; Anna van't Hoog; Jay K Varma; Natalia Vezhnina; Constantia Voniatis; Marije Vonk Noordegraaf-Schouten; Diana Weil; Karin Weyer; Robert John Wilkinson; Takashi Yoshiyama; Jean Pierre Zellweger; Mario Raviglione
Journal:  Eur Respir J       Date:  2015-09-24       Impact factor: 16.671

View more
  2 in total

Review 1.  Precision Vaccine Development: Cues From Natural Immunity.

Authors:  Soumik Barman; Dheeraj Soni; Byron Brook; Etsuro Nanishi; David J Dowling
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

2.  Tuberculosis-specific antigen stimulated and unstimulated interferon-γ for tuberculous meningitis diagnosis: A systematic review and meta-analysis.

Authors:  Fangyu Shi; Xia Qiu; Mingjing Yu; Yan Huang
Journal:  PLoS One       Date:  2022-08-30       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.